CXCR3 and hepatocellular carcinoma: Of note, we have previously reported RNA sequencing analysis after dual antibody blockade of VEGFR2 and PD-1 antibody using the same orthotopic HCC model, but found no difference in CXCL10 or CXCR3 expression.21 These data indicate that upregulation of the CXCL10/CXCR3 axis may be due to the multitargeted (VEGFR-independent) activity of regorafenib.